How to buy Antisense Therapeutics shares | A$0.115

Own Antisense Therapeutics shares in just a few minutes.


Fact checked

Antisense Therapeutics Limited is a drug manufacturers—specialty & generic business based in Australia. Antisense Therapeutics shares (ANP) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.115 – the same closing value as a week prior. Antisense Therapeutics has a trailing 12-month revenue of around $668,433.

How to buy shares in Antisense Therapeutics

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Antisense Therapeutics. Find the share by name or ticker symbol: ANP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Antisense Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of $0.115, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of Antisense Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Antisense Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Antisense Therapeutics's share price has had significant positive movement.

Its last market close was $0.115, which is 34.78% up on its pre-crash value of $0.075 and 296.55% up on the lowest point reached during the March crash when the shares fell as low as $0.029.

If you had bought $1,000 worth of Antisense Therapeutics shares at the start of February 2020, those shares would have been worth $468.75 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,796.88.

Antisense Therapeutics share price

Use our graph to track the performance of ANP stocks over time.

Antisense Therapeutics shares at a glance

Information last updated 2020-09-25.
Latest market closeAUDA$0.115
52-week rangeAUDA$0.029 - AUDA$0.13
50-day moving average AUDA$0.0905
200-day moving average AUDA$0.0699
Target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) AUDA$-0.008

Share Trading Account Offer

IG Share Trading Offer


Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

  • Brokerage - AU shares: From AUD 5 or 0.05%
  • Brokerage - US shares: USD 0
  • Sign-up process: Instant
  • Support - After hours: Yes
Go to site
More info

Important: Share trading carries risk of capital loss.


Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data indicated here is updated regularly
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
Finder Award
IG Share Trading
AUD 8 or 0.1%
AUD 50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares, Forex, CFDs, Margin trading
Brokerage discount: $5 on Australian shares for active traders & $0 commission on US and global shares
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
CMC Markets Stockbroking
AUD 11 or 0.1%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, mFunds
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.
ThinkMarkets Share Trading
ASX shares, ETFs
Fast sign-up: Start trading in just a few minutes
Switch between your ASX share trading account and your forex account on your mobile and access some of the lowest brokerage fees on the market with a flat $8 commission (until $200,000).
ANZ Share Investing
AUD 19.95
ASX shares, Global shares, Margin trading, Options trading
Earn 1 Qantas Point per AU$3 spent on brokerage fees on certain instruments.
Access Morningstar reports, company announcements and and live pricing via ANZ’s share investing platform. Available for desktop and mobile.
Westpac Online Investing Account
AUD 19.95 or 0.11%
AUD 63.50 per year on the global markets account
ASX shares, Global shares, Options trading, US shares

Compare up to 4 providers

Is it a good time to buy Antisense Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Antisense Therapeutics price performance over time

Historical closes compared with the close of A$0.115 on 2020-09-29

1 week (2020-09-23) 0%
1 month (2020-08-28) 26.37%
3 months (2020-06-30) 55.41%
6 months (2020-03-30) 144.68%
1 year (2019-09-30) 47.44%
2 years (2018-09-28) 538.89%
3 years (2017-09-29) 216.80%
5 years (2015-09-30) 36.42%

Antisense Therapeutics financials

Revenue TTM $668,433
Gross profit TTM $464,631
Return on assets TTM -82.84%
Return on equity TTM -160.97%
Profit margin 0%
Book value 0.009
Market capitalisation $56.2 million

TTM: trailing 12 months

Antisense Therapeutics share dividends

We're not expecting Antisense Therapeutics to pay a dividend over the next 12 months.

Have Antisense Therapeutics's shares ever split?

Antisense Therapeutics's shares were split on a 1:10 basis on 5 November 2013. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Antisense Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Antisense Therapeutics shares which in turn could have impacted Antisense Therapeutics's share price.

Antisense Therapeutics share price volatility

Over the last 12 months, Antisense Therapeutics's shares have ranged in value from as little as $0.029 up to $0.13. A popular way to gauge a stock's volatility is its "beta".

ANP.AU volatility(beta: 1.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Antisense Therapeutics's is 1.1747. This would suggest that Antisense Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Antisense Therapeutics overview

Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.

Frequently asked questions

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site